Takeda Pharmaceutical Company Limited history, profile and history video
Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical and biopharmaceutical company headquartered in Tokyo, Japan.
HISTORY
Takeda was founded in 1781 when Chobei Takeda I started his business and began selling traditional Japanese and Chinese herbal medicines in Osaka, Japan.
In 1895, the company acquired Uchibayashi Drug Works to establish its own factory in Osaka and became a pharmaceutical manufacturer.
In 1907, the company obtained sales rights in Japan for products from Bayer, and became the first company in Japan to produce saccharin.
In 1915, the R&D division, Takeda Pharmaceutical Company, which researched and developed new pharmaceutical products, was formed.
In 1925, the company was incorporated as Chobei Takeda & Co., Ltd.
In 1925, Chobei Takeda & Co., Ltd. also merged with Takeda Pharmaceutical Company.
In 1943, the company changed its name to Takeda Pharmaceutical Industries, Ltd. (its English name was changed to Takeda Chemical Industries, Ltd. in 1961).
In 1949, the company was listed on the Tokyo and Osaka stock exchanges.
In 1985, Takeda formed TAP Pharmaceuticals Inc. in the U.S. in a 50:50 joint venture with Abbott Laboratories.
In 2005, the U.S. bio-venture Syrrx, Inc. was acquired.
In 2008, the company acquired Millennium Pharmaceuticals, Inc., one of the world’s largest biopharmaceutical companies.
In 2011, the Swiss pharmaceutical company Nycomed was acquired.
In 2012, Takeda acquired URL Pharma, Inc., the Brazilian pharmaceutical company Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda., LigoCyte Pharmaceuticals, Inc., and Envoy Therapeutics, Inc.
In 2017, Takeda acquired ARIAD Pharmaceuticals.
In 2019, Takeda acquired Shire Plc, becoming one of the largest global biopharmaceutical companies.
OPERATIONS
The company focuses on the following key business areas: Oncology, Rare Diseases, Neuroscience, Gastroenterology, Plasma-Derived Therapies, and Vaccines.
Oncology
The Oncology segment focuses on discovering, developing, and delivering breakthrough oncology therapies.
Rare Diseases
The Rare Diseases segment aspires to transform the treatment of rare diseases in immunology, hematology, metabolic, and lysosomal storage disorders.
Neuroscience
The Neuroscience segment aspires to provide innovative medicines to patients suffering from neurologic and psychiatric diseases.
Gastroenterology
The Gastroenterology segment delivers innovative medicines and dedicated patient disease support programs.
Plasma-Derived Therapies
The Plasma-Derived Therapies segment provides plasma-derived therapies that are life-saving medicines for thousands of people with rare and complex diseases rely on.
Vaccines
The Vaccines segment is addressing unmet medical needs through vaccine development against infectious diseases.
With more than 49,000 employees, Takeda Pharmaceutical Co., Ltd. is considered one of the largest pharmaceutical companies in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. According to Forbes, it is considered one of the top 2000 largest public companies in the world.
*Information from Forbes.com, Wikipedia.org, and ”www.takeda.com”.
**Video published on YouTube by “Armando Javier“.